A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.

ABSTRACT:

Background

A phase II study was performed to investigate the safety and efficacy of weekly doses of combined paclitaxel and 5-fluorouracil (5-FU) with concurrent radiation therapy, followed by 2 cycles of consolidation chemotherapy to treat patients with advanced oesophageal carcinoma.

Methods

The eligibility criteria included local, advanced, newly diagnosed and postoperative local regional lymph node metastasis; an Eastern Cooperative Oncology Group (ECOG) score of ≤ 2; and adequate organ function. Patients received chemoradiotherapy consisting of radiotherapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx) and concurrent paclitaxel (50 mg/m²) and 5-FU (300 mg/m²) for 96 h on days 1, 8, 15, 22, and 29. The two-cycle consolidation chemotherapy protocol included pacli

SUBMITTER: Xia Y 

PROVIDER: S-EPMC5341476 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature